New Delhi: In a landmark development for Atmanirbhar Bharat, the government on Wednesday launched India’s first indigenous CRISPR-based gene therapy for Sickle Cell Disease (SCD), particularly affecting the country’s tribal population. The therapy, named “BIRSA 101” in honour of tribal freedom fighter Bhagwan Birsa Munda, was unveiled by Union Minister of State (Independent Charge) for Science and Technology.
Described as “precise genetic surgery,” the therapy can not only cure SCD but also transform treatment for other hereditary disorders, the Minister said. SCD, a chronic single-gene disorder, leads to severe anaemia, painful episodes, organ damage, and reduced life expectancy.
Dr. Singh stated, “India has formally begun its decisive journey towards becoming a Sickle Cell Disease–free nation, marking a historic turning point in public health and genomic medicine.” He highlighted that the therapy aligns with PM Modi’s vision of a Sickle Cell–Free India by 2047 and strengthens India’s leadership in affordable medical technology.
Developed at CSIR-Institute of Genomics and Integrative Biology (IGIB), BIRSA 101 offers a low-cost alternative to overseas gene therapies, which cost ₹20–25 crore. IGIB has partnered with the Pune-based Serum Institute of India to scale up the therapy using the engineered enFnCas9 CRISPR platform.
Dr. Umesh Shaligram, Executive Director of Serum Institute, said, “Globally, gene therapies cost over three million dollars and are out of reach for most. Our mission is to bring Indian innovation to the poorest of the poor.”
This breakthrough underscores India’s growing capability in affordable, cutting-edge genomic therapies. (Agencies)
